Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Secukinumab
Cosentyx
Routinely available
SMC ( SMC2592)
07/08/2024
Indication
For the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. SMC restriction: for use in adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsu...
Therapeutic Area
Skin
Status Description
Routinely available in line with national guidance
Formulation
150 mg or 300 mg solution for injection in pre-filled pen or pre-filled syringe